HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
about
Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosisT cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residuesSimultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"Epstein-barr virus sequence variation-biology and diseaseNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineFunctional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapyThe Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradationDendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.The Epstein-Barr virus and its association with human cancers.Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vectorCD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections.Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio.Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individualsComplete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferHLA associations with nasopharyngeal carcinoma.Infection of human endothelial cells with Epstein-Barr virus.Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memoryImmune regulation in Epstein-Barr virus-associated diseasesPotential selection of LMP1 variants in nasopharyngeal carcinoma.The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma.Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.Latent antigen vaccination in a model gammaherpesvirus infection.The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines.Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1.TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection.Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance.Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
P2860
Q24657081-118E176D-41D9-4052-9F93-5A8B9D2226CFQ24679910-E405CBAF-64B0-42C9-8F27-43FC28DFE292Q24814428-B6E1D37B-B5A8-4171-B404-57D32202D403Q27003183-58C293E2-6F5A-4996-8F1C-0A152BD14E70Q28749468-F5AC8289-0448-4210-A2A5-6154831D98FCQ33305203-AD4E7683-5E08-4B0E-B95E-506220DC3914Q33396983-4FEE621F-9CF9-4CD6-9EFD-D7665B339F4DQ33825567-211CC0C6-A171-47B0-81B0-2CA487BFA930Q33882153-CB6EFC9F-D319-4562-B309-2900C01EC56AQ35222179-DBBB07D6-E17F-43EF-B3EE-1063431F9F8AQ35238310-2D8A0AA6-CAEC-4FA5-B912-89569A3518B2Q35660783-974A93D9-AC5E-420E-914A-D1D5E826FA4DQ35661383-83E9F5B9-3B58-4AE8-8055-A3F475DB1942Q35731386-00E0FD39-2A50-4E1D-8F49-F917FE732DEAQ35852557-4820CB1F-F212-49AE-8506-64C1421D027DQ35865462-41DC237E-48B0-4103-ADB1-9D259439F25BQ36059593-0E3F6DFA-DFF6-4471-8714-1F090E53DB7AQ36125265-5B8296DB-568D-4420-9B65-26B1A8604110Q36365385-94096B86-2A99-4175-80E3-4796F0BE88B5Q36367550-2C797E46-D0E9-442C-8F37-99C062C5E5E3Q36669953-30BDC697-E512-4F4F-B38A-04A5E62C5C79Q36944141-54A400D6-AD8A-4324-9CE6-28BD67BE16E7Q38264787-E1C51F4E-0350-491B-80AD-407C328EC237Q39581864-14CE7372-A00B-4C37-B5F0-18BB7C487829Q39606886-97CCE2D9-3397-4DD3-8FAC-EE888CBE1226Q39736862-5B668369-9E77-4AC2-A17E-B766CC9AB255Q39871191-24D2EF6F-8B44-47FB-995E-D78508A291B1Q39874070-5F38A007-1E31-4291-99C4-0E6A0C224E5CQ39875574-F9F457D6-EDB7-44D8-9209-B21A1A67244CQ39876882-636DB69A-5F0E-43E5-83E0-B782DF426A9FQ40064164-C4B7FEC8-6C3F-4172-A7B4-A161EEE522ACQ40529241-4D6CD65A-6FF6-4FA5-9E24-75E169966A82Q40720422-BB580482-F000-49DB-BC33-FA7D69F527C9Q40848717-18012E6F-FF64-4684-A64E-2A777A0ECCA5Q42048053-959E0FD8-0835-4C05-A353-25421B8D2C2EQ42175278-4741B1C2-E588-4A64-8089-10DF6AD7C049Q42632595-1CB3614A-5589-4AF1-9662-BF3F42789FB8Q42938727-3391AE88-90D6-4949-9B80-EA77878DD860Q45728634-D1ACA04A-3309-4C14-BF17-A1B0183A7A7FQ52691571-5F8E0653-17D0-423F-8E64-DA9640E14E8A
P2860
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@ast
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@en
type
label
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@ast
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@en
prefLabel
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@ast
HLA A2.1-restricted cytotoxic ...... latent membrane protein LMP2.
@en
P2093
P2860
P1433
P1476
HLA A2.1-restricted cytotoxic ...... n latent membrane protein LMP2
@en
P2093
Rickinson AB
P2860
P304
P577
1993-12-01T00:00:00Z